Loading...
NASDAQ: IMDX
Insight Molecular Diagnostics Inc.
Healthcare · Biotechnology
Market Cap
$112.36M
52w High
$8.51
52w Low
$2.33
P/E
-2.07
Volume
161.07K
Outstanding Shares
28.66M
Company profile
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally.
CEOJoshua Riggs
SectorHealthcare
IndustryBiotechnology
Employees46
IPO dateDec 30, 2015
Valuation
Forward P/E—
EV/EBITDA-0.44
Enterprise value$26.14M
Stock splits
Jul 25, 20231:20
Profitability & growth
Revenue growth126.09%
Gross margin54.73%▲43.17%vs FY2023
Operating margin-1,392.91%▼94.04%vs FY2023
ROE494.24%▲464.14%vs FY2023
Analyst consensus
RatingBuy
Target price$10.50▲167.86%
7
Buy
4
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
Mar 23, 2026
View
EPS
Actual vs estimate by quarter
Q1FY25
ActualEst.
-$0.26
-$0.24
Q2FY25
ActualEst.
-$0.30
-$0.23
Q3FY25
ActualEst.
-$0.34
-$0.24
Q4FY25
Next Est.
—
Revenue
Actual vs estimate by quarter
Q1FY25
ActualEst.
$2.14M
$126.78K
Q2FY25
ActualEst.
$518K
$300K
Q3FY25
ActualEst.
$260K
$285K
Q4FY25
Next Est.
—